Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database...
-
2018 (v1)PublicationUploaded on: April 14, 2023
-
2021 (v1)Publication
Hepatocellular carcinoma prognosis depends on both liver and tumor determinants, especially on maximum tumor diameter, multifocality, and presence of portal vein thrombosis, despite apparently complete tumor removal by resection or liver transplantation.
Uploaded on: April 14, 2023 -
2019 (v1)Publication
The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated. We sought to explore the relationship among the ITA.LI.CA prognostic variables (i.e., tumor stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of etiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years.
Uploaded on: March 27, 2023 -
2022 (v1)Publication
No description
Uploaded on: February 11, 2024 -
2022 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2018 (v1)Publication
The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS],...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Background: Dichotomous models like Milan Criteria represent the routinely used tools for predicting the outcome of patients with hepatocellular carcinoma (HCC). However, a paradigm shift from a dichotomous to continuous prognostic stratification should represent a good strategy for improving the prediction process. Recently, the tumor burden...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background & aims: Alcohol abuse and metabolic disorders are leading causes of hepatocellular carcinoma (HCC) worldwide. Alcohol-related aetiology is associated with a worse prognosis compared with viral agents, because of the lower percentage of patients diagnosed with HCC under routine surveillance and a higher burden of comorbidity in...
Uploaded on: February 13, 2024 -
2018 (v1)Publication
Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of re-staging patients before proceeding with additional...
Uploaded on: April 14, 2023